Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. Also, patients with brain metastases from RCC are not allowed in most clinical trials, and there is an unmet need for treatment of […]

read more

ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are stopped from getting to the brain by a membrane called the blood-brain barrier. Most patients with brain metastases have, therefore, been excluded from phase 3 clinical trials. In the phase 3/4 CheckMate 920 study, presented at […]

read more

Potential role for routine brain imaging in advanced kidney cancer

A recent study published in Journal of the National Comprehensive Cancer Network suggests that brain scans should be considered in most patients with metastatic kidney cancer. 1,689 people with metastatic renal cell carcinoma (RCC) had MRI brain scans for entry into clinical trials. Of these, 4% had brain metastases that did not show any symptoms. […]

read more

ASCO GU 2021: Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. In this study, the results of which will be presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) […]

read more

Treatment of brain metastases for kidney cancer patients

Brain metastases in patients with renal cell carcinoma (RCC) is actually fairly uncommon, occurring in around 8% to 10% of all patients with metastatic RCC. Unfortunately, RCC brain metastases have been poorly studied and have a poor outcome, often with a median overall survival as low as 3 months in people with multiple brain metastases. […]

read more

Patterns of initial metastatic recurrence after surgery for high-risk kidney cancer patients

This study looked at where metastases occurred after surgery for high-risk non-metastatic renal cell carcinoma (RCC). The study also identified the factors that indicated outcomes for these patients. A total of 1,057 patients with stage T3a or greater RCC were treated with surgery. 160 patients (59.3%) had one site of initial metastatic recurrence, while 110 […]

read more

Systemic therapy for the treatment of metastatic kidney cancer brain metastases

Research published in Clinical Genitourinary Cancer this month looked at the use of systemic therapy for the treatment of patients with spread of metastatic renal cell carcinoma (RCC) to the brain (brain metastases). In recent years, the use of modern radiotherapy has resulted in significant improvements in the control and overall survival of RCC that has […]

read more

Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib

In this video interview from Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about some interesting data on brain metastases in patients who have received a combination therapy. Renal cell carcinoma (RCC) patients will develop brain metastases in about 10% to 20% of the time, and the treatment for […]

read more

ASCO GU 2020: Immunotherapy combinations effective for brain metastases

Two small studies reported on patients whose kidney cancer had spread into the brain at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. The first study was a real-world report of 17 patients with advanced kidney cancer in the brain. The patients were treated with ipilimumab and […]

read more

Nivolumab and kidney cancer brain metastases

Results from a recent trial suggest that nivolumab has limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma (mRCC). Around 10% of patients with metastatic RCC develop metastases in the brain. Since the results of this trial are negative and do not impact clinical practice, the study brings into question […]

read more
Showing 1 to 10 of 16 results
  TOP